id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-347091-wbjpa5st	Davis, Matthew R.	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19	2020-07-10		.txt	text/plain	5078	233	44	In the intention-to-treat population, no difference was observed in time to clinical improvement in the remdesivir group compared to patients receiving placebo (median 21 days [IQR [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] There was also no difference in discharges by day 14 (25% vs. However, due to an evolving understanding of the protracted nature of COVID-19 disease progression, trial statisticians blinded to study data proposed a change in the primary outcome to time to recovery, defined as the first day a patient satisfies ordinal scale categories 1, 2, or 3. While these data support a small benefit of remdesivir in this patient population in terms of time to clinical improvement, there does not appear to be a difference in progression of severity of disease or death, likely because of the low incidence rate of these end points in mild-moderately ill patients.	./cache/cord-347091-wbjpa5st.txt	./txt/cord-347091-wbjpa5st.txt